Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on October 22, 2018, regarding events occurring on October 18, 2018. The filing discloses the appointment of a new Chief Financial Officer (CFO) and the terms of her employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the appointment of Kamalam Unninayar as Chief Financial Officer, effective November 26, 2018. Prior to this role, Ms. Unninayar served as CFO at Tetraphase Pharmaceuticals, Inc. and held various finance positions at Thermo Fisher Scientific, Inc.
Guidance, Outlook, and Compensation Terms
The filing details the specific compensatory arrangements for the new CFO:
- Base Salary: $340,000 annually.
- Annual Bonus: Target of 50% of base salary, subject to a 0 to 2x multiplier based on performance.
- Equity Awards: Total value of $140,000 at issuance, split between $70,000 in non-qualified stock options and $70,000 in restricted stock units. Both vest in four equal annual installments.
- Termination Provisions:
- Without Cause/Good Reason: 18 months of base salary paid over one year, plus pro-rated bonus and accelerated vesting of options vesting within 12 months.
- Change in Control: If terminated within 3 months prior to or 12 months after a Change in Control, the executive receives a lump sum equal to 18 months of base salary and immediate acceleration of all stock options and awards.
- Contract Term: Initial one-year term, automatically extending for two additional years unless notice is given 90 days prior to the anniversary.
The filing does not provide specific guidance on future revenue or operational outlook beyond the executive appointment.
Investor Verification Checklist
- Verify the commencement date of the new CFO (November 26, 2018) and the transition plan for the previous finance leadership.
- Review the specific performance metrics defined by the Board for the annual bonus multiplier (0 to 2x).
- Confirm the fair market value used for the exercise price of the $70,000 stock option grant.
- Assess the impact of the 18-month severance package on the company's cash reserves in the event of an unexpected departure.